Literature DB >> 9537440

(Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells.

S Roth1, K Michel, A M Gressner.   

Abstract

Cultured parenchymal liver cells (PC) were recently recognized to contain (latent) transforming growth factor beta (TGF-beta) while the expression of TGF-beta mRNA remains controversial. This study was designed to analyze PC in different microenvironments (liver in situ, highly purified, isolated, and cultured PC) regarding the qualitative and quantitative content of mature and latent TGF-beta protein (immunostainings, enzyme-linked immunosorbent assay [ELISA], and enzyme-labeled fluorescence [ELF] technique). The results were compared with its gene expression (reverse-transcription polymerase chain reaction [RT-PCR]). In all microenvironments, PC contained latent TGF-beta, which was partially activated after cell isolation and culture. The amount of total TGF-beta (mature plus latent) of latency-associated peptide (LAP) and of latent TGF-beta binding protein (LTBP) were shown to decrease during culture. In contrast, TGF-beta2 and TGF-beta3 mRNA and LTBP-1 and -3 mRNA expression were first detectable after culture. Permeabilization of cell membranes in whole liver and of isolated PC with streptolysin O or carbon tetrachloride, respectively, released TGF-beta, a part of which was integrated in the large latent complex as estimated by analytical gel filtration chromatography. The TGF-beta released by damaged PC induces paracrine effects on hepatic stellate cell cultures. It stimulates hyaluronan synthesis and antagonizes the effect of mitogenic factor(s) of PC on [3H]thymidine incorporation. The results strongly suggest that the main part of hepatocellular TGF-beta is not generated by de novo synthesis but from uptake into the liver in vivo. The immunodetection of preexisting mature TGF-beta after isolation of the cells is probably caused by intracellular activation of latent TGF-beta. The injury-dependent discharge of TGF-beta from PC might be an important mechanism for initiation and perpetuation of various forms of chronic human liver diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537440     DOI: 10.1002/hep.510270416

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

Authors:  Axel-M Gressner; Chun-Fang Gao; Olav-A Gressner
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

2.  Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

3.  Gli1 activation and protection against hepatic encephalopathy is suppressed by circulating transforming growth factor β1 in mice.

Authors:  Matthew McMillin; Cheryl Galindo; Hae Yong Pae; Gabriel Frampton; Pier Luigi Di Patre; Matthew Quinn; Eric Whittington; Sharon DeMorrow
Journal:  J Hepatol       Date:  2014-07-18       Impact factor: 25.083

4.  Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.

Authors:  Tadashi Namisaki; Ryuichi Noguchi; Kei Moriya; Mitsuteru Kitade; Yosuke Aihara; Akitoshi Douhara; Norihisa Nishimura; Kosuke Takeda; Yasushi Okura; Hideto Kawaratani; Hiroaki Takaya; Kenichiro Seki; Hitoshi Yoshiji
Journal:  J Gastroenterol       Date:  2015-07-21       Impact factor: 7.527

5.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

Review 6.  TGF-β in progression of liver disease.

Authors:  Steven Dooley; Peter ten Dijke
Journal:  Cell Tissue Res       Date:  2011-10-19       Impact factor: 5.249

Review 7.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008

8.  Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options.

Authors:  Olav A Gressner; Ralf Weiskirchen; Axel M Gressner
Journal:  Comp Hepatol       Date:  2007-07-30

Review 9.  Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality.

Authors:  O A Gressner; R Weiskirchen; A M Gressner
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

10.  The liver is populated by a broad spectrum of markers for macrophages. In alcoholic hepatitis the macrophages are M1 and M2.

Authors:  James Lee; B French; T Morgan; Samuel W French
Journal:  Exp Mol Pathol       Date:  2013-10-19       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.